Cancer Letters
Volume 203, Issue 2 , Pages 127-137 , January 2004

The anti-inflammatory potential of berberine in vitro and in vivo

  • Chi-Li Kuo

      Affiliations

    • Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC
    • ,
  • Chin-Wen Chi

      Affiliations

    • Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC
    • Department of Medical Research and Education, Taipei Veterans General Hospital, Rm. 822, Taipei, Taiwan, ROC
    • ,
  • Tsung-Yun Liu

      Affiliations

    • Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan, ROC
    • Department of Medical Research and Education, Taipei Veterans General Hospital, Rm. 822, Taipei, Taiwan, ROC
    • Corresponding Author InformationCorresponding author. Address: Department of Medical Research and Education, Taipei Veterans General Hospital, Rm. 822, Taipei, Taiwan, ROC. Tel.: +886-2-2874-7848; fax: +886-2-2875-1562

Received 16 May 2003 ,Revised 8 September 2003 ,Accepted 8 September 2003.

References 

  1. Ikram M. A review on the chemical and pharmacological aspects of genus Berberis. Planta Med. 1975;28:353–358
  2. Huang KC, Williams WM. Antibacterial, antiviral, and antifungal herbs. in: The pharmacology of Chinese Herbs. New York, NY: CRC Press; 1999; pp. 381–383
  3. Kuo CL, Chou CC, Yung BY. Berberine complexes with DNA in the berberine-induced apoptosis in human leukemic HL-60 cells. Cancer Lett. 1995;93:193–200
  4. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J. Pharm. Pharmacol. 2001;53:763–768
  5. Chi CW, Chang YF, Chao TW, Chiang SH, P'Eng F, W Y, et al. Flowcytometric analysis of the effect of berberine on the expression of glucocorticoid receptors in human hepatoma HepG2 cells. Life Sci. 1994;54:2099–2107
  6. Yasukawa K, Takido M, Ikekawa T, Shimada F, Takeuchi M, Nakagawa S. Relative inhibitory activity of berberine-type alkaloids against 12-O-tetradecanoylphorbol-13-acetate-induced inflammation in mice. Chem. Pharm. Bull. 1991;39:1462–1465
  7. Fukuda K, Hibiya Y, Mutoh M, Koshiji M, Akao S, Fujiwara H. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. J. Ethnopharmacol. 1999;66:227–233
  8. Williams TJ, Jose PJ. Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a. J. Exp. Med. 1981;153:136–153
  9. Issekutz AC, Movat HZ. The effect of vasodilator prostaglandins on polymorphonuclear leukocyte infiltration and vascular injury. Am. J. Pathol. 1982;107:300–309
  10. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature-New Biol. 1971;231:232–235
  11. Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA. 1991;88:2692–2696
  12. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem. Biophys. Res. Commun. 1995;208:582–589
  13. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc. Natl Acad. Sci. USA. 1975;72:3073–3076
  14. Seibert K, Zhang Y, Leahy K, Hauser S, Masferrer J, Perkins W, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl Acad. Sci. USA. 1994;91:12013–12017
  15. Anonymous, Cancer Registry Annual Report in Taiwan Area: 2000, Department of Health, Executive Yuan, ROC, 2001.
  16. Yamauchi T, Watanabe M, Kubota T, Hasegawa H, Ishii Y, Endo T, et al. Cyclooxygenase-2 expression as a new marker for patients with colorectal cancer. Dis. Colon Rectum. 2002;45:98–103
  17. Wang Z, Fuentes CF, Shapshay SM. Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell. Laryngoscope. 2002;112:839–843
  18. Shamma A, Yamamoto H, Doki Y, Okami J, Kondo M, Fujiwara Y, et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 2000;6:1229–1238
  19. Tang DW, Lin SC, Chang KW, Chi CW, Chang CS, Liu TY. Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma-evidence for COX-2 induction by areca quid ingredients in oral keratinocytes. J. Oral Pathol. Med. (2003); 522–529
  20. Jeng JH, Ho YS, Chan CP, Wang YJ, Hahn LJ, Lei D, et al. Areca nut extract up-regulates prostaglandin production, cyclooxygenase-2 mRNA and protein expression of human oral keratinocytes. Carcinogenesis. 2000;21:1365–1370
  21. Wong DY, Chang KW, Chen CF, Chang RC. Characterization of two new cell lines derived from oral cavity human squamous cell carcinomas—OC1 and OC2. J. Oral. Maxillofac. Surg. 1990;48:385–390
  22. Sedgwick AD, Lees P. Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents Actions. 1986;18:429–438
  23. Yang IW, Chou CC, Yung BY. Dose-dependent effects of berberine on cell cycle pause and apoptosis in Balb/c 3T3 cells. Naunyn Schmiedebergs Arch. Pharmacol. 1996;354:102–108
  24. Subbaramaiah K, Cole PA, Dannenberg AJ. Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. Cancer Res. 2002;62:2522–2530
  25. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
  26. Balch CM, Dougherty PA, Cloud GA, Tilden AB. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients. Surgery. 1984;95:71–77
  27. Eling TE, Thompson DC, Foureman GL, Curtis JF, Hughes MF. Prostaglandin H synthase and xenobiotic oxidation. Annu. Rev. Pharmacol. Toxicol. 1990;30:1–45
  28. Fukutake M, Yokota S, Kawamura H, Iizuka A, Amagaya S, Fukuda K, et al. Inhibitory effect of Coptidis Rhizoma and Scutellariae Radix on azoxymethane-induced aberrant crypt foci formation in rat colon. Biol. Pharm. Bull. 1998;21:814–817
  29. Chen CM, Chang HC. Determination of berberine in plasma, urine and bile by high-performance liquid chromatography. J. Chromatogr. B, Biomed. Appl. 1995;665:117–123
  30. Miyazaki H, Shirai E, Ishibashi M, Niizima K. Quantitative analysis of berberine in urine samples by chemical ionization mass fragmentography. J. Chromatogr. A. 1978;152:79–86

PII: S0304-3835(03)00594-9

doi: 10.1016/j.canlet.2003.09.002

Cancer Letters
Volume 203, Issue 2 , Pages 127-137 , January 2004

Article Tools

* Image Usage & Resolution